Jinan Central Hospital

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomi...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

Effects of vegetarian or vegan diets on cardiovascular metabolic health in patients with cardiovascular disease: a systematic review and meta-analysis

Vegetarian or vegan diets have been associated with favorable cardiovascular outcomes in the general population; however, their effects on cardiometabolic risk factors in patients with established cardiovascular disease (CVD) remain unclear. This systematic review and meta-analys...

ID4 enhances ferroptosis sensitivity in gastric cancer by promoting ubiquitination degradation of GPX4

Gastric cancer (GC) is one of the most prevalent malignant tumors worldwide, presenting a serious threat to human health due to its high fatality rates and incidence. Ferroptosis, as a novel form of programmed cell death, demonstrates significant potential in cancer therapy. The...